Combined use of ribavirin and interferon beta in demyelinating diseases
The present invention is in the field of neurological disorders. It relates to the use of a compound of formula (I) in combination with an interferon (IFN) for the manufacture of a medicament for treatment and/or prevention of a demyelinating disease. In particular, it relates to the use of a combination of Ribavirin and IFN-beta for treatment and/or prevention of a demyelinating disease, such as multiple sclerosis.
1 - 19 . (canceled)
20 . A method of treating or preventing a demyelinating disease comprising the administration of a composition comprising a compound of formula (I)
wherein
R 1 is selected from the group comprising or consisting of hydrogen, acyl, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkyl aminocarbonyl, C 1 -C 6 -alkyl amino, C 1 -C 6 -alkyl alkoxy, C 1 -C 6 -alkyl sulfanyl, C 1 -C 6 -alkyl sulfinyl, C 1 -C 6 -alkyl sulfonyl, aryl, heteroaryl, C 3 -C 8 -cycloalkyl or C 3 -C 8 membered heterocycloalkyl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 1 -C 6 alkyl cycloalkyl containing optionally 1-3 heteroatoms, C 2 -C 6 -alkenyl-aryl or -heteroaryl, C 2 -C 6 -alkynyl aryl or -heteroaryl, sulfonyl or phosphoryl;
R 2 is selected from the group comprising or consisting of hydrogen C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, hydroxy, halogen;
R 3 is selected from the group comprising or consisting of hydrogen, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl;
A is N or CR 4 wherein
R 4 is H or NR 5 R 5′ wherein
R 5 and R 5′ are independently from each other selected from the group comprising or consisting of hydrogen, acyl, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkyl aminocarbonyl, C 1 -C 6 -alkyl amino, C 1 -C 6 -alkyl alkoxy, C 1 -C 6 -alkyl sulfanyl, C 1 -C 6 -alkyl sulfinyl, C 1 -C 6 -alkyl sulfonyl, C 1 -C 6 -alkyl sulfonylaminoaryl, aryl, heteroaryl, C 3 -C 8 membered cycloalkyl or heterocycloalkyl, C 1 -C 6 alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 1 -C 6 alkyl cycloalkyl containing optionally 1-3 heteroatoms, C 2 -C 6 -alkenyl-aryl or -heteroaryl, C 2 -C 6 -alkynyl aryl or -heteroaryl, sulfonyl or phosphoryl.
R 3 and R 5 may form a heterocyclic ring together;
and a composition comprising an interferon-beta (IFN-β), or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, to an individual in need of said treatment.
21 . The method according to claim 20 , wherein R 1 is H.
22 . The method according to claim 20 , wherein R 2 is OH.
23 . The method according to claim 20 , wherein R 3 is H.
24 . The method according to claim 20 , wherein A is N.
25 . The method according to claim 20 , wherein R 3 and R 5 form a 6-membered heterocyclic ring.
26 . The method according to claim 20 , wherein the heterocyclic ring is a pyrimidine or a pyrimidine-one.
27 . The method according to claim 20 , wherein the compound is 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide (Ribavirin).
28 . The method according to claim 20 , wherein said demyelinating disease is multiple sclerosis.
29 . The method according to claim 20 , wherein said fused protein comprises an Ig fusion.
30 . The method according to claim 20 , wherein said functional derivative comprises at least one moiety attached to one or more functional groups, which occur as one or more side chains on the amino acid residues.
31 . The method according to claim 30 , wherein said moiety is a polyethylene moiety.
32 . The method according to claim 20 , wherein said IFN-β is administered at a dosage of about 1 to 50 μg per person per day, or about 10 to 30 μg per person per day or about 10 to 20 μg per person per day.
33 . The method according to claim 20 , wherein said IFN-β is administered daily or every other day.
34 . The method according to claim 20 , wherein said IFN-β is administered twice or three times per week.
35 . The method according to claim 20 , wherein said IFN-β is administered subcutaneously.
36 . The method according to claim 20 , wherein said IFN-β is administered intramuscularly.
37 . The method according to claim 20 , wherein said compound is administered at a dosage of about 100 to 2000 mg per person per day, or about 400 to 1200 mg per person per day, or about 800 to 1000 mg per person per day, or about 1000 to 1200 mg per person per day.
38 . The method according to claim 20 , wherein said compound is administered orally.
39 . The method according to claim 20 , wherein said compositions are administered simultaneously, sequentially, or separately.
40 . The method according to claim 20 , wherein said compound and said IFN-β are administered as a single composition.
41 . The method according to claim 20 , wherein said compound and said IFN-β are administered as different compositions.